ViraPower™ Adenoviral Gateway™ Expression Kit

본 제품은 액체 질소로 배송 및 보관되는 세포 관련 제품으로, 해당 제품 구매 시 세포 사용 가이드라인을 반드시 확인해주십시오. 세포사용가이드라인 다운로드

본 제품은 LMO 제품으로, 고객 분께서 LMO 신고 시스템을 통해 직접 수입 신고를 진행해주셔야 합니다. 자세히보기

인용 및 참조 문헌 (7)

Invitrogen™

ViraPower™ Adenoviral Gateway™ Expression Kit

Invitrogen’s ViraPower™ Adenoviral Expression System은 in vitro 또는 in vivo에서 replication-incompetent adenovirus를 사용해 분할(dividing) 및 비분할(non dividing) 포유류 세포에 대한자세히 알아보기

카탈로그 번호	수량
K493000	1 kit

카탈로그 번호 K493000

제품 가격(KRW)

1,907,000

キャンペーン価格

Ends: 31-Mar-2026

2,243,000

할인액 336,000 (15%)

카트에 추가하기

1 kit

제품 가격(KRW)

1,907,000

キャンペーン価格

Ends: 31-Mar-2026

2,243,000

할인액 336,000 (15%)

카트에 추가하기

Invitrogen’s ViraPower™ Adenoviral Expression System은 in vitro 또는 in vivo에서 replication-incompetent adenovirus를 사용해 분할(dividing) 및 비분할(non dividing) 포유류 세포에 대한 표적 유전자 전달을 원활하게 합니다. ViraPower™ Adenoviral Expression System은 Gateway™ 재조합 클로닝 기술을 이용해 클로닝을 간편하게 하고 높은 역가의 재조합 adenovirus 생성 효율을 크게 높입니다. 이 키트에는 pAd⁄CMV⁄V5-DEST Gateway™-adapted adenoviral vector가 들어있어 인간 cytomegalovirus (CMV) immediate-early enhancer⁄promoter)와 293A cell line에서 높은 수준의 단백질 발현이 가능합니다.

주요 장점:
• 농축 과정을 통해 최대 1 x 1011 pfu⁄ml 고역가 adenoviral stock을 생성합니다.
• 고효율의 빠른 Gateway™ Recombination Cloning는 인간 또는 박테리아 세포에서 효율적이고 균일한 재조합 체를 생성
• 배양액 또는 in vivo에서 관심 유전자를 활성 분할 및 비분할 포유류 세포에 효율적으로 전달
• High-throughput 어플리케이션 또는 라이브러리 transfer 어플리케이션에 맞게 조정 가능
• 시스템의 생물 안전성이 높고 유전자 전달체로써의 사용이 가능한 replication-incompetent virus 생성

For Research Use Only. Not for use in diagnostic procedures.

구성 또는 유도성 시스템Constitutive

배달 유형Adenoviral

용도(애플리케이션)Viral Expression

제품 유형Adenoviral Expression Kit

수량1 kit

벡터pAd

클로닝 방법Gateway

제품라인Gateway, ViraPower

프로모터CMV

단백질 태그V5 Epitope Tag

Unit SizeEach

구성 및 보관

pAd⁄CMV⁄V5-DEST Gateway™ Vector: store at -20°C;.
293A Cells: store in liquid nitrogen.
Guaranteed stable for 6 months when properly stored.

자주 묻는 질문(FAQ)

Can I perform the single-step protocol for the BP/LR Clonase reaction using BP Clonase enzyme and LR Clonase enzyme instead of BP Clonase II enzyme and LR Clonase II enzyme?

In the single-step protocol for the BP/LR Clonase reaction, we would not recommend substituting the BP Clonase II/LR Clonase II enzymes with BP Clonase /LR Clonase enzymes as this would result in very low recombination efficiency.

Do you have a recommended single-step protocol for BP/LR recombination?

Yes, we have come up with a single-step protocol for BP/LR Clonase reaction (http://www.thermofisher.com/us/en/home/life-science/cloning/gateway-cloning.html#1), where DNA fragments can be cloned into Destination vectors in a single step reaction, allowing you to save time and money.

How can I move my gene of interest from a Gateway-adapted expression clone to a new Destination vector as I have lost the entry clone?

We would recommend performing a BP reaction with a Donor vector in order to obtain an entry clone. This entry clone can then be used in an LR reaction with the Destination vector to obtain the new expression clone.

Can I purchase the 5X LR Clonase buffer or 5X BP Clonase buffer separately?

We do not offer the 5X LR Clonase buffer and 5X BP Clonase buffer as standalone products. They are available as part of the enzyme kits.

Do you offer Gateway vectors for expression in plants?

We do not offer any Gateway vectors for expression in plants.

View all ViraPower™ Adenoviral Gateway™ Expression Kit FAQs

인용 및 참조 문헌 (7)

인용 및 참조 문헌

Abstract

The receptor for parathyroid hormone and parathyroid hormone-related peptide is hydrolyzed and its signaling properties are altered by directly binding the calpain small subunit.

Authors:Shimada M, Mahon MJ, Greer PA, Segre GV,

Journal:Endocrinology

PubMed ID:15691895

'We show calcium-dependent, direct binding between the N-terminal portion of the PTH/PTHrP receptor (PTH1R) C-terminal intracellular tail and the calpain small subunit. Binding requires, but may not be limited to, amino acids W474, S475, and W477. The wild-type, full-length rat (r) PTH1R, but not rPTH1R with W474A/W477A substitutions, copurifies with ... More

p116Rip targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/ROCK-regulated neuritogenesis.

Authors:Mulder J, Ariaens A, van den Boomen D, Moolenaar WH,

Journal:Mol Biol Cell

PubMed ID:15469989

Activation of the RhoA-Rho kinase (ROCK) pathway stimulates actomyosin-driven contractility in many cell systems, largely through ROCK-mediated inhibition of myosin II light chain phosphatase. In neuronal cells, the RhoA-ROCK-actomyosin pathway signals cell rounding, growth cone collapse, and neurite retraction; conversely, inhibition of RhoA/ROCK promotes cell spreading and neurite outgrowth. The ... More

Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.

Authors:Happel KI, Lockhart EA, Mason CM, Porretta E, Keoshkerian E, Odden AR, Nelson S, Ramsay AJ,

Journal:Infect Immun

PubMed ID:16113296

Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of ... More

Estrogen related receptors stimulate pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression.

Authors:Zhang Y, Ma K, Sadana P, Chowdhury F, Gaillard S, Wang F, McDonnell DP, Unterman TG, Elam MB, Park EA,

Journal:J Biol Chem

PubMed ID:17079227

The pyruvate dehydrogenase complex (PDC) catalyzes the conversion of pyruvate to acetyl-CoA in mitochondria and is a key regulatory enzyme in the oxidation of glucose to acetyl-CoA. Phosphorylation of PDC by the pyruvate dehydrogenase kinases (PDK2 and PDK4) inhibits PDC activity. Expression of the PDK genes is elevated in diabetes ... More

Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2.

Authors:Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I,

Journal:J Biol Chem

PubMed ID:15863501

Human group III secreted phospholipase A(2) (sPLA(2)-III) consists of a central group III sPLA(2) domain flanked by unique N- and C-terminal domains. We found that the sPLA(2) domain alone was sufficient for its catalytic activity and for its prostaglandin E(2) (PGE(2))-generating functions in various cell types. In several if not ... More

View all ViraPower™ Adenoviral Gateway™ Expression Kit citations